| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cd708a84f841d099bd81f8e8d72a610a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4525 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16 |
| filingDate |
2007-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66e5f8d3fdbb8d55fad2e24c60c6625e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39f15a75576a98a2a063d2c27e470722
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80bbfa5b33091a4e8d9b4f406e561194
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c30bac0238a89ffb3f88d983fe6a5a7a |
| publicationDate |
2010-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-101674820-A |
| titleOfInvention |
The method of using histone deacetylase inhibitors and monitoring biomarkers in therapeutic alliance |
| abstract |
Provided hereinly be: use the method that at least a histone deacetylase inhibitor reduces the cell DNA repairing activity; Use the method that at least a biomarker monitoring cell DNA repairing activity reduces; Reduce the cell DNA repairing activity by at least a histone deacetylase inhibitor of application in therapeutic alliance and treat method for cancer; Combinational therapeutic methods, wherein at least a histone deacetylase inhibitor disturbs the DNA repair mechanism that relates to RAD51; Predict that first of at least a histone deacetylase inhibitor is used and second the method for inducing period between using of at least a other therapeutic treatment; With the pharmaceutical composition that is used for therapeutic alliance. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103310105-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112485233-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103324846-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103191412-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109490543-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103796514-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115023416-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109416925-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112485233-B |
| priorityDate |
2006-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |